Supplementary appendix

This appendix formed part of the original submission

Phase I Epicovid-19 questionnaire and Phase 2 ValidSymptoms Section of Epicovid-19 questionnaire

COVID-19 NATIONAL EPIDEMIOLOGICAL SURVEY (EPICOVID19)

Phase I questionnaire

SOCIO-DEMOGRAPHIC DATA

- **1.** Sex at birth* M |__ | F |__ |
- 2. Year of birth * |_|_|_|
- 3. Ethnicity*
- |__| Europe
- |__| Asia
- |__| North America
- |__| Central/South America
- |__| Africa
- |__| Oceania
- |__| Other
- 4. Postal code* |_|_|_|
- 5. Municipality* |_____

6. Education*

- |__| None
- Primary school
- |__| Middle high school
- |__| High school
- |__| University degree
- Post graduate degree (PhD, vocational master, medical specialization)

7. Occupational status*

- |__| Employed
- ___ Student
- |__| Unemployed

- |__| Retired
- |__| Other

8. Last occupation*

- |___| Armed forces occupations
- |__| Managers
- |__| Intellectual and scientific professionals (e.g. clinicians, engineers, researchers, teachers)
- [__] Technicians and associate professionals (e.g. healthcare technicians, IT technicians)
- |__| Clerk
- |__| Service and sales workers (e.g. merchants, sales persons)
- Craft and related trades workers
- |__| Plant and machine operators, assemblers, and drivers of vehicles
- |__| Other

CLINICAL EVALUATION

9. Did you have one or more of the following symptoms since the 1st of February 2020? *

|__| Fever with a temperature greater than 37.5 °C for at least three consecutive days

- |__| Cough
- Sore throat/rhinorrea
- |__| Headache
- |__| Myalgia
- Olfactory or taste disorders
- |__| Shortness of breath
- |__| Chest pain
- |__| Feelings of having a fast-beating
- Gastrointestinal disorders (diarrhoea, nausea, vomiting)
- |__| Conjunctivitis
- |__| Pneumoniae

10. If you had at least one of the symptoms above, please indicate in which month they occurred for the first time *

- | | February
- |__| March
- ___ April

11. Have you ever been diagnosed with one or more of the following conditions?

- Lung diseases (e.g. asthma, obstructive pulmonary disease)
- |_| Heart diseases (e.g. ischemic heart disease, atrial fibrillation)
- |__| Hypertension
- |__| Kidney diseases
- |__| Immune system diseases (e.g. thyroid disease, psoriasis, rheumatoid arthritis)
- |__| Tumours
- |__| Metabolic diseases (e.g. diabetes, obesity, gout)
- Liver diseases (e.g. hepatitis, cirrhosis, liver failure)
- |___| Depression and/or anxiety

12. Please indicate other conditions

- Surgical procedures under general anaesthesia during the last year
- ___ Transplants
- | | Allergies
- Pregnancy
- |__| Non self-sufficient in carrying out daily activities
- |__| Healthcare workers (e.g. clinicians, nurses, rescuer, pharmacist)

13. Did you carry out the following vaccinations?*

- Flu shot during the last autumn
- Anti-pneumococcal in the last 12 months - Other vaccinations in the last 12 months

_ Yes	No
Yes	No
Yes	No

14. Do you regularly take one or more of the following medicines?

- ___ Aspirin
- | | Anti-hypertensive
- |___| Hypocholesterolemic drugs
- | Anti-diabetics
- |__| Anti-cancer drugs
- | | Corticosteroids
- |__| Thyroid drugs (e.g. euthyrox)
- |__| Anti-inflammatory drugs
- |__| Anxiety medications and/or sedatives
- |__ | Anti-depressant
- |__| Supplements (e.g. vitamins)

If females

•	•	
4	_	
	-	
T	ວ.	

Have you ever been taking birth pills and/or hormone replacement therapy?*

| | No

|__| Yes, in the past, for less than 5 years

- |_| Yes, in the past, for more than 5 years
- |__| Yes currently, taking it less than 5 years
- |__| Yes currently, taking it more than 5 years

16. Indicate the number of completed pregnancies*

 0
 1

- |__| 2
- | | 3 or more

17. Have you been in a close contact (direct contact at a distance of less than 2 meters, or in a closed environment such as a house, workplace, transportation vehicles) with confirmed COVID-19 cases, live or deceased?*

|__| Yes |__| No

18. Have you been in a close contact (direct contact at a distance of less than 2 meters, or in a closed environment such as a house, workplace, transportation vehicles) with suspected COVID-19 cases, live or deceased?*

| Yes | No | I don't know

19. Did you contact the emergency number and/or the general practitioner to report any symptoms of suspected infection by COVID-19?*

- | | No
- No but I went to the hospital on my own initiative
- | | Yes, and they suggested to me isolation
- |_ | Yes, and they did not suggest to me isolation
- _ Yes, and I was sent to the hospital

20. Have you been tested for COVID-19? *

- |__| Yes, with a positive result
- |__| Yes, with a negative result
- | | Yes, but I do not know the result
- |___ No, I did not perform any test

21. Have you been hospitalized due to COVID-19, either as a suspected or as a confirmed case?*

22. Please indicate other elements that might be of relevance for COVID-19

PERSONAL CHARACTERISTICS AND HEALTH STATUS

23. How would you describe your health in general?*

|__ | Very bad |__ | Bad |__ | Adequate |__ | Good |__ | Very good

24. Do you fear getting infected with the coronavirus (COVID-19)?*

- |__| No
- |___ | Just a little bit
- |__| Neutral
- |__| Quite enough
- |__| Yes, a lot

25. Do you fear your family being infected with the coronavirus (COVID-19)?*

- |__| No
- |__| Just a little bit
- |__| Neutral
- |__| Quite enough
- |__| Yes, a lot

HOUSING CONDITIONS

26. Your home is located in:*

- |__| City centre with more than 100.000 inhabitants
- |__| Suburbs of cities with more than 100.000 inhabitants
- Small town
- |__| Countryside

27. Your home is located in an area where the road traffic is:*

- |__| Intense (living near a busy road)
- |__| Moderate
- Low

28. How many rooms there are in your home (excluding the bathroom and auxiliary spaces)?*

|__| One |__| Two |__| Three |__| More than three

29. Besides you, how many people live in your household?*

|__| None |__| One |__| Two |__| More than two

30. Are there in the same household elderly persons or anyone with immunocompromising or chronic disease conditions?*

|_| Yes |_| No

LIFESTYLE

31. How many people have you been in contact with in average, prior to the Governmental restrictions on lockdown?*

|__| Less than 10 |__| Between 10 and 100 |__| More than 100

32. Do you smoke?*

|_| I have never smoked or I smoked less than 100 cigarettes in my lifetime

- |_| I am a former smoker (I have smoked at least 100 cigarettes in my lifetime and I do not smoke anymore)
- |_| Yes, smoking less than 10 cigarettes per day
- |__| Yes, smoking between 10 and 20 cigarettes per day
- |__| Yes, smoking more than 20 cigarettes per day (more than one pack per day)

If former smoker

33. How many year have you smoked?* |__|

If current smoker 34. How many years?* |__|

35. Prior to the lockdown by the Governmental restrictions, for how long did you follow a regular routine of moderate or intense physical activity (swimming, racing)?*

- |__| Not doing any physical activity or doing it for less than 10 minutes per week
- |__| Between 10 minutes and two hours and half per week
- |__| More than two hours and half per week

BEHAVIOURS FOLLOWING THE LOCKDOWN

36. Please indicate your employment status following the restrictions introduced by the Italian Government since March, 9th 2020 *

- |_ | Continued going to work at my workplace
- |__| Working from home
- |__| I had to stop working due to the emergency
- |__| I am not employed

37. Since March, 9th 2020, how many times do you go out during a week? *

- |__| Never
- |__| 1
- |__| 2-3
- |__| 4-5
- |__| 6 or more

38. Since March, 9th 2020, do you use public transport go to work or to provide supplies*

- |__| No, never
- |__| Yes, 1-3 times per week
- |__| Yes, 4-6 times per week
- |__| Yes, 7 or more times per week

Phase II questionnaire

Laboratory test results

Please answer the questions below regarding the results of the laboratory tests you have carried out

A1. Have you made one or more swabs with a POSITIVE result? *

__| Yes |__| No

A2. Indicate the date of the FIRST POSITIVE Swab

A3. With reference to your FIRST POSITIVE SWAB, enter the viral load, if available

A4. Indicate the number of elapsed days from the beginning of the symptoms to the day of the FIRST POSITIVE SWAB

A5. Have you made one or more swabs with a NEGATIVE result? *

A6. Indicate the date of the LAST NEGATIVE SWAB

A7. Have you performed the serological test too? *

|__| Yes |__| No

A8. Indicate the outcome of the serological test for Immunoglobulin G (IgG) Antibodies:

|__| Positive

|__| Negative

A9. Indicate the outcome of the serological test for Immunoglobulin M (IgM) Antibodies:

__ | Positive

|__| Negative

A10. Indicate the number of elapsed days from the beginning of the symptoms to the day in which the serological test was performed:

Thank you for your cooperation!

APPENDIX

Respondents and non-respondents to the Phase I and Phase II survey

	Respondents Phase I and Phase II	Respondents only to Phase I	
	(n° 2703)	(n ° 4161)	p value
Age	49.6, ±14.7	46.2, ±13.1	0.014
Positive Nasopharyngeal swab	706 (26.1%)	862 (20.7%)	<0.0001
Female	1841 (68.14%)	2669 (64.1%)	0.001
Ethnicity	2666 (98.60%)	4133 (99.3%)	0.005
Lower educational status	151 (5.6%)	17 (0.4%)	<0.0001
Medium educational status	837 (31.0%)	1019 (24.5%)	
High educational status	1715 (63.4%)	3125 (75.1%)	
Self-reported comorbidities			
Lung diseases (e.g. asthma, obstructive pulmonary disease)	196 (7.3%)	297 (7.1%)	0.859
Heart diseases (e.g. ischemic heart disease, atrial fibrillation)	103 (3.8%)	120 (2.9%)	0.034
Hypertension	361 (13.4%)	567 (13.6%)	0.748
Kidney diseases	22 (0.8%)	33 (0.8%)	0.925

Immune system diseases (e.g. thyroid disease, psoriasis, rheumatoid arthritis)	266 (9.8%)	365 (8.8%)	0.134
Tumours	88 (3.3%)	121 (2.9%)	0.413
Metabolic diseases (e.g. diabetes, obesity, gout)	124 (4.6%)	161 (3.9%)	0.145
Liver diseases (e.g. hepatitis, cirrhosis, liver failure)	21 (0.8%)	29 (0.7%)	0.703
Depression and/or anxiety	194 (7.2%)	265 (6.4%)	0.190

APPENDIX

Supplementary appendix

This appendix formed part of the original submission

(1) Identification of Critical Factors by Exploratory and confirmatory factor analysis

The factor structure of the COVID-19 self-reported symptoms items was tested using two procedures: Exploratory factor analysis (EFA)¹ and confirmatory factor analysis (CFA)². Exploratory factor analysis (EFA) is a variable reduction technique which identifies the number of latent constructs and the underlying factor structure of a set of variables. Confirmatory factor analysis (CFA) is a statistical technique used to verify the factor structure of a set of observed variables. CFA allows testing the hypothesis that a relationship between the observed variables and their underlying latent constructs exists. In the first step, EFA and PA (parallel analysis) were performed to identify item performance (loadings) and to define the number of factors underlying the scale. EFA was applied using tetrachoric correlation matrix and two solutions were tested with one and two factors. PA was performed (1000 random correlation matrices) to establish the number of factors underlying the scale. Classical criteria from EFA were used: eigenvalue rule according Kaiser's rule of thumb³, only a factor with eigenvalue > 1 explained more of the variance, scree plot (n° of factors before the break in the eigenvalue plot), Horn's parallel analysis (number of factors with eigenvalue higher than average random eigenvalues), and factor-loading rule (item-factor correlations >0.35).

(2) Confirmation of presence of latent variable by Confirmatory Factor Analysis (CFA)

A Confirmatory Factor Analysis (CFA) via Structural Equation Modeling (SEM) was performed to confirm the presence of a one latent variable (factors) underlying the COVID-19 self-reported symptoms items. The items (endogenous variables) are (S1) *Fever, with temperatures above 37.5* ° *C for at least three consecutive days*, (S2) Cough, (S3) Sore throat and/or cold, (S4) Headache, (S5) Pain in muscles, bones, joints, (S6) Loss of taste and / or smell, (S7) Respiratory difficulty (sense of breathlessness at rest), (S8) Chest pain (sternum

pain), (S9) Tachycardia, (S10) Gastrointestinal complaints (diarrhea, nausea, vomiting), (S11) Conjunctivitis (red eyes). Several goodness-of-fit criteria was use4⁴: (i) Standardized Root Mean Square Residual (SRMR); (ii) Root Mean Square Error of Approximation (RMSEA). In general, a model is considered to show good fit when the SRMR and RMSEA are not higher than 0.10. In addition, further CFA indexes as gamma for unidimensionality (AVE; average variance extracted acceptable if > 0.4) and the general validity coefficient (McDonald's Omega acceptable if > 0.8) verify the adequacy of single-factor measurement model and the factor validity index (rho) for the evaluation of the correlation factor with the variables⁵. Finally, the standardized factor loadings (item-factor correlations) (acceptable if > 0.4) proved high-quality specific factor validity for each item and determinacy coefficient (DC) >0.90 as construct validity index.

(3) Development of optimal scoring algorithm by Homogeneity Analysis

After evaluating the unidimensionality through exploratory and confirmatory factor analyses

an optimal questionnaire score by Homogeneity Analysis (Multiple Correspondence Analysis)⁶ was constructed. Through the HOMALS procedure we replaced item dichotomous responses (Yes/No) with category quantifications: the score is the sum of the subject's item responses, once they are recoded by category quantifications. Category quantifications assigned by HOMALS to the dichotomous items are named "optimal" quantifications because they maximize homogeneity among items and minimize measurement error. Subsequently, the COVID-19 self-reported optimal score was rescaled to a range of 0 -10 using: 10*(EPICOVID 19 score - min)/(max - min). The result of this equation was used as the EPICOVID 19 self-reported optimal score for each individual, a continuous trait that summarizes the common components of COVID-19 self-reported symptoms items. With more details the subject score is:

EPICOVID 19 optimal score =
$$\begin{cases} 0 & \text{if "NO"} \\ \frac{q_{YESj} - q_{NOj}}{\sum_{j=1}^{p} (q_{YESj} - q_{NOj})} & \text{if "YES"} \end{cases}$$

the figures q^{YESj} and q^{NOj} are the HOMALS optimal quantifications of the "Yes" and "No" binary item responses, respectively ⁶. Additionally, Cronbach Index (α) which is a scale reliability coefficient based on the internal consistency, and Greenacre Index (τ) which is the percentage of inter-item association explained by the first dimension, were also computed

(4) Validation of the Scoring algorithm by receiver operating characteristics (ROC)

Hence, the score validation was performed by receiver operating characteristics (ROC) analysis was performed to evaluate the COVID-19 self-reported symptoms items effectiveness in distinguishing symptomatic individuals severity. With the aim of discriminating between different severity of symptoms, for each EPICOVID 19 factor score built, sensitivity, specificity, and youden's index were computed with two

reference standard⁷: a) subjects with NPS + vs subjects with NPS - ; b) subjects with serological IgG(+) vs subjects with IgG(-).Overall, predictive performance was measured by the AUC (Area Under the Curve): ROC curves with AUC of 0.5 indicating no predictive diagnosis versus AUC of 1.0 indicating perfect ones. The Youden index (J), a statistic that captures the performance of a diagnostic test, computed as J = sensitivity + specificity - 1, was used to identify the optimal cut point⁸. All statistical analyses were done using R software (version 3.6.3)

1. Gorsuch RL. Common factor analysis versus component analysis: Some well and little known facts. *Multivariate Behavioral Research* 1990, **25**, 33-39.

2. Gifi A. Nonlinear multivariate analysis. New York: John Wiley & Sons 1990 (First edition 1981, Department of Data Theory, University of Leiden).

3. Bartholomew DJ, Knott M. Latent variable models and factor analysis. 1999, 2nd ed. New York: Oxford University Press.

4. Hooper D, Coughlan J, Mullen M. Structural Equation Modelling: Guidelines for Determining Model Fit. *Electronic Journal of Business Research Methods* 2008; **6**(1), 53-60.

5. McDonald RP. Theoretical foundations of principal factor analysis and alpha factor analysis. *Br J Math Stat Psychol* 1970; **23**:1-21.

6. Greenacre M. Correspondence analysis in the social sciences. London: Academic Press; 1994.

7. Choi BC. Slopes of a receiver operating characteristic curve and likelihood ratios for a diagnostic test. *Am J Epidemiol* 1998; **148**: 1127–32

8. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. *Epidemiology* 2005;**16**:73e81

APPENDIX

One factor solution extracted by Principal-Component Factors

	Symptoms items	One-factor solution
(S1) days	Fever, with temperatures above 37.5 ° C for at least three consecutive	0.653
(S2)	Cough	0.702
(\$3)	Sore throat and/or cold	0.571
(S4)	Headache	0.721
(\$5)	Pain in muscles, bones, joints	0.815
(S6)	Loss of taste and / or smell	0.732
(S7)	Respiratory difficulty (sense of breathlessness at rest)	0.723
(S8)	Chest pain (sternum pain)	0.736
(S9)	Tachycardia (Palpitation)	0.707

(S10) Gastrointestinal complaints (diarrhea, nausea, vor	niting)
--	---------

(S11) Conjunctivitis (red eyes)

0.606

0.762

APPENDIX

Standardized coefficients and goodness of fit indexes for one factor model.

	Standardized coefficients	Std.Err	z-value	P(> z)
(S1) Fever, with temperatures above 37.5 $^{\circ}$ C for at least three consecutive days	0.646	0.020	31.657	<0.0001
(S2) Cough	0.666	0.020	33.816	<0.0001
(S3) Sore throat and/or cold	0.537	0.023	23.752	<0.0001
(S4) Headache	0.697	0.019	37.296	<0.0001
(S5) Pain in muscles, bones, joints	0.814	0.016	51.722	<0.0001
(S6) Loss of taste and / or smell	0.724	0.019	38.974	<0.0001
(S7) Respiratory difficulty (sense of breathlessness at rest),	0.688	0.021	32.710	<0.0001
(S8) Chest pain (sternum pain)	0.701	0.021	33.122	<0.0001

(S9) Tachycardia	0.675	0.023	29.201	< 0.0001
(S10) Gastrointestinal complaints (diarrhea, nausea, vomiting)	0.737	0.018	42.009	<0.0001
(S11) Conjunctivitis (red eyes)	0.557	0.027	20.373	<0.0001
	AVE; average variance ex	stracted		0.516
	McDonald's Omega	McDonald's Omega		
	Factor validity index (rho)		0.951
	SRMR-Standardized Roo	t Mean Square Resi	dual	0.072
	RMSEA-Root Mean Squa	are Error of Approx	imation	0.052
	CFI-Comparative fit inde	X		0.977
	TLI-Tucker-Lewis index			0.971